It is injected directly into the tumor, but its effectiveness has a broader range of action that also prevents the appearance of distant metastases.
Clinical Trials
High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem
Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications.
Neoadjuvant Immunotherapy Trial Sees High pCR Rates in Stage III Melanoma
A new study suggests a short course of immunotherapy before surgery may significantly improve outcomes in patients with high-risk melanoma.
Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma
Adjuvant nivolumab (Opdivo) in combination with ipilimumab (Yervoy) significantly improved 3-year distant metastasis–free survival (DMFS) rates compared with historical controls in patients with high-risk uveal melanoma, according to findings from the phase 2 HCRN MEL17-309 trial (NCT03528408) presented at the 2024 ASCO Annual Meeting.